Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer - Seite 2
Laetitia Rouxel, designated Chief Financial Officer of Evotec SE, commented : "I am thrilled to join the very talented and passionate team of Evotec, a company with a strong sense of purpose to improve disease understanding through data, science and biology. I bring my expertise as CFO in worldwide environments, along with a commitment of high quality in execution. I am looking forward to co-building and further leveraging innovation at Evotec to reach the next stage in its sustainable growth path."
Laetitia Rouxel has more than 25 years of finance experience in various sectors such as Life Sciences, Food, Cosmetics and Building industry. After graduating from the French Business school "ISG", she started her career with finance and commercial roles in the Pharma industry at Pfizer and J&J. After working for the French multinational food-products corporation Danone, where she covered various leading Finance positions in multiple regions for R&D, Medical and Baby Nutrition based in France and in the Netherlands, she then joined the beauty company Coty in Switzerland in 2018, where she became divisional CFO, before being nominated Global CFO of Wavin, a solutions leader for the building and infrastructure industry.
Lesen Sie auch
ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The
Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class
pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800
biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g.
neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has
to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,500 highly
qualified people. The Company's 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec
and LinkedIn .